CFB

2-CHLORO-9-(2-DEOXY-2-FLUORO-B -D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE

Find entries where: CFB

is present as a standalone ligand in 3 entries

Find related ligands:

Chemical Component Summary
Name	2-CHLORO-9-(2-DEOXY-2-FLUORO-B -D-ARABINOFURANOSYL)-9H-PURIN-6-AMINE
Synonyms	CLOFARABINE
Identifiers	(2R,3R,4S,5R)-5-(6-amino-2-chloro-purin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
Formula	C₁₀ H₁₁ Cl F N₅ O₃
Molecular Weight	303.677
Type	NON-POLYMER
Isomeric SMILES	c1nc2c(nc(nc2n1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)Cl)N
InChI	InChI=1S/C10H11ClFN5O3/c11-10-15-7(13)5-8(16-10)17(2-14-5)9-4(12)6(19)3(1-18)20-9/h2-4,6,9,18-19H,1H2,(H2,13,15,16)/t3-,4+,6-,9-/m1/s1
InChIKey	WDDPHFBMKLOVOX-AYQXTPAHSA-N

Chemical Details
Formal Charge	0
Atom Count	31
Chiral Atom Count	4
Bond Count	33
Aromatic Bond Count	10

Drug Info: DrugBank

DrugBank ID	DB00631
Name	Clofarabine
Groups	approved investigational
Description	Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other types of treatment have failed. It is not known if the drug extends life expectancy. Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been investigated.
Synonyms	Clofarabina 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine Clofarabin Cl-F-Ara-A Clofarabine Clofarabinum 2-chloro-9-(2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)adenine CAFdA (2R,3R,4S,5R)-5-(6-amino-2-chloropurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
Brand Names	Clofarabine Clolar Ivozall Evoltra
Indication	For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
Categories	Adenine Nucleotides Antimetabolites Antineoplastic Agents Antineoplastic and Immunomodulating Agents Arabinonucleosides BCRP/ABCG2 Substrates Drugs that are Mainly Renally Excreted Heterocyclic Compounds, Fused-Ring Hypotensive Agents Immunosuppressive Agents Myelosuppressive Agents Narrow Therapeutic Index Drugs Noxae Nucleic Acid Synthesis Inhibitors Nucleic Acids, Nucleotides, and Nucleosides Nucleoside Metabolic Inhibitor Nucleosides Nucleotides OAT3/SLC22A8 Substrates OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index OCT2 Substrates with a Narrow Therapeutic Index Purine Analogues Purine Nucleotides Purines Ribonucleotides Toxic Actions
ATC-Code	L01BB06
CAS number	123318-82-1

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
DNA	-	unknown	other/unknown
DNA polymerase alpha catalytic subunit	MAPVHGDDSLSDSGSFVSSRARREKKSKKGRQEALERLKKAKAGEKYKYE...	unknown	inhibitor
Ribonucleoside-diphosphate reductase large subunit	MHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSG...	unknown	inhibitor
Deoxycytidine kinase	MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEV...	unknown	substrate
ATP-binding cassette sub-family G member 2	MSSSNVEVFIPVSQGNTNGFPATASNDLKAFTEGAVLSFHNICYRVKLKS...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682